O2 TREATMENT IN COVID-19

---

Yıldız E.

Presentation, pp.85-86, 2020

• Publication Type: Other Publication / Presentation
• Publication Date: 2020
• Page Numbers: pp.85-86
• Kütahya Health Sciences University Affiliated: Yes

Abstract

Background

The clinical course of COVID-19, which is our

global problem, is variable. Advanced age,

hypertension, diabetes, chronic lung disease,

asthma, chronic kidney diseases, liver

diseases, cancer, obesity and tobacco use

are risk groups. In the course of COVID-19,

severe pneumonia ranging from

asymptomatic patients to ARDS can be seen.

It is estimated that the average time from

the onset of symptoms to the development

of acute respiratory distress syndrome

(ARDS) is 8 days, during this time, pulse

oximetry monitoring is recommended for

patients in the risk group.

Aim

O2 is a widely used and highly

recommended therapy in China. However,

asymptomatic or mild COVID-19 has not

been adequately considered in the current

guidelines. Shen et al. in his work; He

reported that O2 supplementation can

impair virus replication, improve antiviral

immune response, reduce ACE 2 expression,

and especially nighttime O2 therapy can

delay the progression of COVID-19.